目的 探究芪藶強(qiáng)心膠囊聯(lián)合替格瑞洛和阿司匹林治療陳舊性心肌梗死的療效。方法 選取2016年1月-2018年2月?lián)P州大學(xué)醫(yī)學(xué)院附屬興化市人民醫(yī)院60例陳舊性心肌梗死患者作為研究對(duì)象，采用隨機(jī)數(shù)字法將患者分為對(duì)照組和觀察組，每組30例。對(duì)照組患者口服替格瑞洛片，初始劑量采用單次負(fù)荷劑量180 mg，此后90 mg/次，2次/d。同時(shí)口服阿司匹林腸溶片，1片/次，1次/d。觀察組在對(duì)照組基礎(chǔ)上給予芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組均治療和觀察周期為12個(gè)月。比較兩組患者的血清超敏-C反應(yīng)蛋白（hs-CRP）、白血胞介素6（IL-6）水平、左室射血分?jǐn)?shù)（LVEF）、左室舒張末內(nèi)徑（LVEDD）、左室收縮末期容積（LVESV），主要心腦血管不良事件（MACE）、出血事件的發(fā)生情況。結(jié)果 治療后，hsCRP、IL-6的水平均較治療前顯著下降（P<0.05），且觀察組hs-CRP、IL-6水平顯著低于對(duì)照組（P<0.05）。治療后，兩組患者的LVEF均較治療前上升，LVEDD和LVESV均較治療前降低（P<0.05），且觀察組變化幅度均大于對(duì)照組（P<0.05）。治療期間，觀察組患者的MACE發(fā)生率低于對(duì)照組（P<0.05）；觀察組出血事件與對(duì)照組相比，差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合替格瑞洛和阿司匹林治療陳舊性心肌梗死療效顯著，可有效緩解陳舊性心肌梗死患者的血管炎性反應(yīng)，使心功能得到顯著改善，降低MACE的發(fā)生率。

Objective To explore the efficacy of Qiliqiangxin Capsules combined with ticagrelor and aspirin in treatment of old myocardial infarction. Methods A total of 60 patients with old myocardial infarction in Xinghua People's Hospital affiliated to Yangzhou University Medical College from January 2016 to February 2018 were selected as the research objects, and the patients were divided into control group and observation group by random number method, with 30 patients in each group. Patients in the control group were po administered with Ticagrelor Tablets, the initial dose was 180 mg with a single load, then 90 mg/time, twice daily. At the same time, Aspirin Enteric-coated Tablets were taken, one tablet/time, once daily. Patients in the observation group were po administered with Qiliqiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Both groups were treated and observed for 12 months. After treatment, the serum levels of hs-CRP, IL-6, LVEF, LVEDD, LVESV, MACE, and bleeding events were in two groups were compared. Results After treatment, the levels of hs-CRP and IL-6 were significantly decreased compared with those before treatment (P<0.05), and the levels of hs-CRP and IL-6 in the observation group were significantly lower than those in the control group (P<0.05). After treatment, LVEF in two groups were increased compared with that before treatment, LVEDD and LVESV were decreased (P<0.05), and the change amplitude of patients in the observation group was greater than that in the control group (P<0.05). During treatment, the incidence of MACE in the observation group was lower than that in the control group (P<0.05). There was no significant difference in bleeding events between the observation group and the control group. Conclusion Qiliqiangxin Capsules combined with ticagrelor and aspirin in treatment of old myocardial infarction is significant, can effectively alleviate vascular inflammatory response, so that the heart function has been significantly improved, and reduce the incidence of MACE.

R972